Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | 3004334 | PO / MO |
The patient took fourth dose of Vivotif five days after the first dose; Case reference number US-BN-2025-001574 is a spontaneous case initially received from a pharmacist via Communication (reference number: USBAV25-2320) on 18-Sep-2025 and concerns a 71-years-old female patient. The patient's medical history and concomitant medication details were not provided. On 12-Sep-2025, the patient took the first dose of Vivotif (batch number: 3004334) at an unknown dose, orally, for indication of vaccination. On 14-Sep-2025, two days after the first dose, the patient took the second dose of Vivotif (batch number: 3004334) at an unknown dose, orally. On 16-Sep-2025, four days after the first dose, the patient took the third dose of Vivotif (batch number: 3004334) at an unknown dose, orally. On 17-Sep-2025, five days after the first dose, the patient took the fourth dose of Vivotif (batch number: 3004334) at an unknown dose, orally (explicitly coded as 'inappropriate schedule of product administration'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information reported.; Reporter's Comments: A 71-year-old female patient took the fourth dose of Vivotif for indication of vaccination five days after the first dose, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of vaccine administered is considered as listed per company convention. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 71-year-old female patient took the fourth dose of Vivotif for indication of vaccination five days after the first dose, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of vaccine administered is considered as listed per company convention. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.